meropenem-vaborbactam
Selected indexed studies
- Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. (Antimicrob Agents Chemother, 2020) [PMID:32094128]
- Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. (Expert Rev Anti Infect Ther, 2020) [PMID:32297801]
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. (JAMA, 2018) [PMID:29486041]
_Worker-drafted node — pending editorial review._
Connections
meropenem-vaborbactam is a side effect of
Sources
- Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. (2020) pubmed
- Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination. (2018) pubmed
- Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. (2018) pubmed
- Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. (2020) pubmed
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. (2018) pubmed
- Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. (2023) pubmed
- An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia. (2021) pubmed
- Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. (2018) pubmed
- Meropenem/Vaborbactam-A Mechanistic Review for Insight into Future Development of Combinational Therapies. (2024) pubmed
- Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. (2025) pubmed